MRK merck’s lipfendra® (enlicitide) is the first and only once-daily oral pcsk9 inhibitor approved by the U.S. FDA to reduce ldl-c in adults

MRK merck’s lipfendra® (enlicitide) is the first and only once-daily oral pcsk9 inhibitor approved by the U.S. FDA to reduce ldl-c in adults with hypercholesterolemia